Clinical Commander

Back to dossier
cardio.cardiac-tamponade.post-tavr.v1PRODUCTION
cardio.cardiac-tamponade.post-tavr.v1

Cardiac tamponade — post-TAVR (transcatheter aortic valve replacement)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Post-TAVR tamponade — emergent pericardiocentesis + STAT TEE for perforation site + simultaneous cardiac surgery activation (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic)

Inputs
1
Actions
0
Advance rule
Set
Advance when

TAVR-context tamponade physiology suspected

Patient inputs (10)

TAVR population is older (median 82); higher complication risk + worse outcomes (PARTNER trials)

Compensatory tachycardia in tamponade physiology; or pacing-dependent bradycardia post-TAVR (ESC 2015)

TAVR uses procedural UFH (ACT 250-300); reversal with protamine drives bleeding control (VARC-3; Bhatt 2018)

Many TAVR patients on warfarin/DOAC for AF — pre-procedure status drives reversal strategy (Bhatt Circulation 2018)

Contrast nephropathy risk + DOAC dose-reduction; KDIGO 2021 race-free eGFR (Inker NEJM 2021)

STAT TEE in TAVR suite — perforation site localization (LV apex vs RV free-wall vs annulus) + tamponade physiology + valve seating + AR severity (VARC-3 PMID 34304871; ESC 2015 Class I)

Fluoroscopic identification of guidewire/catheter position at perforation site; aortogram for annulus rupture identification (Yashima 2017)

Hemorrhagic loss quantification + transfusion threshold (ESC 2015)

Coagulopathy quantification for warfarin reversal (Bhatt 2018)

Hypotension is part of Beck triad; rapid accumulation in TAVR setting produces tamponade at small volumes (Spodick Circulation 2003)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningpersistent_bleeding_requiring_emergent_cardiac_surgery
    Persistent pericardial bleeding (>200 mL/h drainage output OR ongoing transfusion requirement) despite drainage + reversal — emergent cardiac surgery mandatory for valve repair/redo, LV apex repair, or annulus repair (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningannulus_rupture_with_extravasation
    Annulus rupture with contrast extravasation visualized on completion aortogram or expanding hemopericardium during TAVR — life-threatening; immediate cardiac surgery for repair (Pasic JACC 2015; Barbanti JACC 2013)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcoronary_occlusion_post_tavr
    Acute coronary occlusion (LM or ostial RCA) post-TAVR with ST elevation, hemodynamic compromise, and pericardial effusion (Ribeiro JACC 2013)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningvalve_embolization_with_aortic_dissection
    Valve embolization (typically into aorta or LVOT) with secondary aortic dissection causing tamponade (VARC-3)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Post-TAVR tamponade — emergent drainage + protamine reversal + simultaneous cardiac surgery readiness (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic; Bhatt Circulation 2018)
axis: post_tavr_tamponade_drainage_reversal_surgical
Selected axis "Post-TAVR tamponade — emergent drainage + protamine reversal + simultaneous cardiac surgery readiness (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic; Bhatt Circulation 2018)" by default fallback (first axis)
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus • IV • rapid bolus then reassess
    triggers: hypotension_pre_drainage
    Bridge preload (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids
    Bridge only — does not address obstruction; particularly important in elderly TAVR population (Roy JAMA 2007)
    rxcui 7512
  • protamine
    first line
    heparin_antagonist
    1 mg per 100 U residual UFH (max 50 mg single dose); typical TAVR dose 30-50 mg given ACT 250-300 procedural target • IV • slow IV over 10 min
    triggers: active_ufh_at_time_of_perforation
    Reverse procedural UFH; standard TAVR tamponade reversal (VARC-3; Bhatt 2018)
    rxcui 8825
  • phytonadione
    first line
    vitamin_k
    10 mg IV slow over 10 min • IV • single dose
    triggers: active_warfarin_with_inr_supratherapeutic
    Vit K reverses warfarin synthesis defect; works over 6-12h (Bhatt Circulation 2018)
    rxcui 8308
  • 4-factor prothrombin complex concentrate
    first line
    pcc_4_factor
    25-50 U/kg based on INR • IV • single dose
    triggers: active_warfarin_with_life_threatening_bleeding
    Immediate factor replacement for warfarin reversal in major bleeding (Bhatt Circulation 2018)
    rxcui 1670383
  • idarucizumab
    first line
    monoclonal_antibody_dabigatran_reversal
    5 g IV (2 × 2.5 g vials) • IV • single dose
    triggers: active_dabigatran_with_life_threatening_bleeding
    RE-VERSE AD (Pollack NEJM 2017 PMID 28793172) — complete reversal within minutes
    rxcui 1716191
  • andexanet alfa
    first line
    modified_factor_xa_decoy
    low dose 400 mg bolus + 4 mg/min × 2h OR high dose 800 mg bolus + 8 mg/min × 2h based on FXa-DOAC dose + timing • IV • bolus + infusion
    triggers: active_apixaban_or_rivaroxaban_with_life_threatening_bleeding
    ANNEXA-4 (Connolly NEJM 2019 PMID 30730782) — rapid anti-FXa reversal
    rxcui 2045114
  • packed red blood cells
    add on
    blood_product
    Goal Hb >7 (>8 if ongoing ischemia); MTP 1:1:1 PRBC:FFP:plt if massive • IV • as needed
    triggers: hemoglobin_lt_8_with_active_bleeding
    TRICC + restrictive transfusion; MTP if massive bleeding (Holcomb JAMA 2015)

outpatient playbook — drug actions (3)

  1. 1. aspirin SAPT lifelong
    rxcui 243670
    81 mg PO daily • PO • daily
    trigger: TAVR without AC indication
    POPULAR-TAVI PMID 32865375 (or per current guidelines)
  2. 2. anticoagulation per indication
    rxcui 11289
    warfarin or DOAC at maintenance dose • PO • per agent
    trigger: Ongoing indication
    Bhatt Circulation 2018
  3. 3. endocarditis prophylaxis per AHA 2021 update for prosthetic valves before high-risk dental procedures
    rxcui 723
    amoxicillin 2 g PO 30-60 min before procedure • PO • single dose pre-procedure
    trigger: High-risk dental procedure with prosthetic valve
    AHA 2021 endocarditis prevention update — prosthetic heart valves remain high-risk indication

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Intra-procedural hypotension/bradycardia/arrest in TAVR suite during catheter manipulation, balloon valvuloplasty, valve deployment, or temporary pacing — STAT TEE for perforation site (VARC-3 PMID 34304871); Post-TAVR hemodynamic decompensation within first 24h post-procedure → late perforation or annulus rupture extravasation (Yashima JACC Cardiovasc Interv 2017); New pericardial effusion on intra-procedural TEE or immediate post-TAVR echo (VARC-3 PMID 34304871).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — post-TAVR (transcatheter aortic valve replacement)** (cardio.cardiac-tamponade.post-tavr.v1).
Phenotype framing: Identify mechanism: LV apex perforation (stiff wire), RV free-wall perforation (pacing wire), annulus rupture (oversizing/calcification), valve embolization with dissection, coronary occlusion (LM, ostial RCA) with secondary effusion (Yashima 2017; Pasic 2015; Ribeiro JACC 2013 coronary obstruction)
Scope: Post-TAVR tamponade — emergent pericardiocentesis + STAT TEE for perforation site + simultaneous cardiac surgery activation (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Post-TAVR tamponade — emergent drainage + protamine reversal + simultaneous cardiac surgery readiness (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic; Bhatt Circulation 2018)**.
1. normal saline 500-1000 mL bolus IV rapid bolus then reassess (isotonic_crystalloid, first line) — Bridge preload (ESC 2015)
2. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction; particularly important in elderly TAVR population (Roy JAMA 2007)
3. protamine 1 mg per 100 U residual UFH (max 50 mg single dose); typical TAVR dose 30-50 mg given ACT 250-300 procedural target IV slow IV over 10 min (heparin_antagonist, first line) — Reverse procedural UFH; standard TAVR tamponade reversal (VARC-3; Bhatt 2018)
4. phytonadione 10 mg IV slow over 10 min IV single dose (vitamin_k, first line) — Vit K reverses warfarin synthesis defect; works over 6-12h (Bhatt Circulation 2018)
5. 4-factor prothrombin complex concentrate 25-50 U/kg based on INR IV single dose (pcc_4_factor, first line) — Immediate factor replacement for warfarin reversal in major bleeding (Bhatt Circulation 2018)
6. idarucizumab 5 g IV (2 × 2.5 g vials) IV single dose (monoclonal_antibody_dabigatran_reversal, first line) — RE-VERSE AD (Pollack NEJM 2017 PMID 28793172) — complete reversal within minutes
7. andexanet alfa low dose 400 mg bolus + 4 mg/min × 2h OR high dose 800 mg bolus + 8 mg/min × 2h based on FXa-DOAC dose + timing IV bolus + infusion (modified_factor_xa_decoy, first line) — ANNEXA-4 (Connolly NEJM 2019 PMID 30730782) — rapid anti-FXa reversal
8. packed red blood cells Goal Hb >7 (>8 if ongoing ischemia); MTP 1:1:1 PRBC:FFP:plt if massive IV as needed (blood_product, add on) — TRICC + restrictive transfusion; MTP if massive bleeding (Holcomb JAMA 2015)

Setting playbook (outpatient) — Long-term TAVR surveillance (annual echo for valve function, gradient progression, PVL/AR); anticoagulation management; late complication surveillance (post-pericardiotomy syndrome, late tamponade, prosthetic valve endocarditis) (VARC-3; Otto JACC 2021 PMID 33342586)
9. aspirin SAPT lifelong 81 mg PO daily PO daily — TAVR without AC indication (POPULAR-TAVI PMID 32865375 (or per current guidelines))
10. anticoagulation per indication warfarin or DOAC at maintenance dose PO per agent — Ongoing indication (Bhatt Circulation 2018)
11. endocarditis prophylaxis per AHA 2021 update for prosthetic valves before high-risk dental procedures amoxicillin 2 g PO 30-60 min before procedure PO single dose pre-procedure — High-risk dental procedure with prosthetic valve (AHA 2021 endocarditis prevention update — prosthetic heart valves remain high-risk indication)

Non-pharmacologic actions:
- TAVR clinic follow-up annually
- Cardiology follow-up q3-6 mo for first year then annually
- Cardiac rehab maintenance if appropriate
- Pacemaker follow-up per device protocol

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- Annulus_rupture_LIMITED_drainage_alone_inadequate_immediate_surgical_repair_required (Pasic JACC 2015)
- Protamine_AVOID_severe_anaphylaxis_history_or_diabetic_on_nph_insulin_relative (drug label)
- Andexanet_caution_with_prothrombotic_risk_thromboembolism_signal_in_annexa_4 (Connolly NEJM 2019)
- Idarucizumab_appropriate_only_for_dabigatran_no_effect_on_xa_drugs (Pollack NEJM 2017)

Monitoring

Regimen monitoring:
- continuous TEE during TAVR complication management (VARC-3)
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post with cardiac output monitoring (Adler 2015)
- echo post drain immediate then q4-6h x 24h then q12-24h x 48h (rapid re-accumulation possible if persistent bleeding)
- serial hemoglobin q2h x 12h then q6h (track ongoing bleeding)
- coagulation correction tracking inr ptt post reversal (Bhatt 2018)
- valve function reassessment for PVL and AR (VARC-3)
- conduction monitoring for new LBBB or complete heart block post TAVR (PARTNER)

Setting (outpatient) monitoring:
- Echo at 1, 6 mo then annually
- CBC + CRP if symptoms suggest recurrence
- INR per anticoagulation

Monitoring phase: Re-accumulation surveillance (TEE/TTE q4-6h × 24h then q12-24h × 48h); serial Hb; coagulation correction tracking; valve function reassessment; conduction monitoring (TAVR commonly causes new LBBB / heart block requiring permanent pacemaker)

Disposition

Current setting: outpatient — Long-term TAVR surveillance (annual echo for valve function, gradient progression, PVL/AR); anticoagulation management; late complication surveillance (post-pericardiotomy syndrome, late tamponade, prosthetic valve endocarditis) (VARC-3; Otto JACC 2021 PMID 33342586)

Disposition criteria:
- No recurrence + stable valve function + completed prophylaxis + anticoagulation stable → routine annual TAVR clinic follow-up

Escalation triggers (move to higher acuity):
- Late post-pericardiotomy syndrome → colchicine + NSAID per Imazio CIRCS PMID 26315582
- Late tamponade (rare beyond 30d) → re-route to acute pathway
- Valve dysfunction (rising gradient, new PVL/AR) → cardiology + cardiothoracic for valve-in-valve or redo
- Prosthetic valve endocarditis → re-route to cardio.infective-endocarditis.core.v1
- Hardware-related complications → device-specific intervention

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Persistent pericardial bleeding (>200 mL/h drainage output OR ongoing transfusion requirement) despite drainage + reversal — emergent cardiac surgery mandatory for valve repair/redo, LV apex repair, or annulus repair (VARC-3 PMID 34304871; ESC 2015 §Iatrogenic)
- [LIFE_THREATENING] Annulus rupture with contrast extravasation visualized on completion aortogram or expanding hemopericardium during TAVR — life-threatening; immediate cardiac surgery for repair (Pasic JACC 2015; Barbanti JACC 2013)
- [LIFE_THREATENING] Acute coronary occlusion (LM or ostial RCA) post-TAVR with ST elevation, hemodynamic compromise, and pericardial effusion (Ribeiro JACC 2013)

Citations

- VARC-3 TAVR endpoint definitions (Généreux JACC 2021 PMID 34304871) + 2020 ACC/AHA Valvular Heart Disease Guideline (Otto JACC 2021 PMID 33342586) + 2015 ESC pericardial diseases (Adler EHJ 2015 PMID 26320112). VARC-3 anchors TAVR-complication classification and management; Otto 2021 anchors TAVR indications + post-procedural antithrombotic strategy; ESC 2015 anchors tamponade physiology + drainage approach. [PMID:34304871](https://pubmed.ncbi.nlm.nih.gov/34304871/)
- Cited evidence (PMID 33342586) [PMID:33342586](https://pubmed.ncbi.nlm.nih.gov/33342586/)
- Cited evidence (PMID 26320112) [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 21737009) [PMID:21737009](https://pubmed.ncbi.nlm.nih.gov/21737009/)

Last reconciled with current guidelines: 2026-05-15.
References
  • VARC-3 TAVR endpoint definitions (Généreux JACC 2021 PMID 34304871) + 2020 ACC/AHA Valvular Heart Disease Guideline (Otto JACC 2021 PMID 33342586) + 2015 ESC pericardial diseases (Adler EHJ 2015 PMID 26320112). VARC-3 anchors TAVR-complication classification and management; Otto 2021 anchors TAVR indications + post-procedural antithrombotic strategy; ESC 2015 anchors tamponade physiology + drainage approach. — PMID:34304871
  • Cited evidence (PMID 33342586) — PMID:33342586
  • Cited evidence (PMID 26320112) — PMID:26320112
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 21737009) — PMID:21737009